Suggested algorithm for initial CLL therapy. ¹Venetoclax is not yet approved for frontline therapy in 17p−, currently in clinical trials. ²Idelalisib is not approved for frontline therapy in 17p− in the United States. Given significant concerns for autoimmune complications or fatal infections reported, would only use if no other options available. ³Alemtuzumab is only available via patient-access programs. Chl, chlorambucil; IWCLL, International Workshop on Chronic Lymphocytic Leukaemia; R-HDMP, rituximab/high-dose methylprednisolone; W&W, watch and wait.